Dopaminergic neuron circuitry in the striatum and related basal ganglia structures

The dopaminergic neuron circuitry in the striatum and related basal ganglia structures is a complex neural network essential for motor control, reward processing, and goal-directed behavior (Frontiers in Neuroanatomy, 2006; Neurology, 2016). This system primarily comprises the nigrostriatal pathway, originating in the substantia nigra pars compacta (SNc) and projecting to the dorsal striatum, and the mesolimbic pathway, originating in the ventral tegmental area (VTA) and projecting to the ventral striatum or nucleus accumbens (MDPI, 2021; Wikipedia, 2024). Within these structures, dopamine acts as a key neuromodulator, influencing the activity of GABAergic medium spiny neurons through D1-like (excitatory) and D2-like (inhibitory) receptors to regulate the balance between the direct and indirect pathways of the basal ganglia (Neurology, 2016; NIH/PubMed, 2011). Pathological alterations in this circuitry are central to several major disorders; for instance, the progressive loss of dopaminergic neurons in the SNc leads to the motor deficits of Parkinson's disease, while dysregulated dopamine signaling is implicated in schizophrenia and addiction (NIH/PubMed, 2007; MDPI, 2021; Yale University, 2024). Therapeutic strategies often involve modulating this circuitry using dopamine precursors like levodopa, dopamine receptor agonists or antagonists, and inhibitors of dopamine degradation or reuptake (Frontiers in Neuroanatomy, 2006; NIH/PubMed, 2007; Yale University, 2024). However, targeting this system is challenging due to the risk of side effects such as levodopa-induced dyskinesia, extrapyramidal symptoms, and impulse control disorders, which arise from the broad influence of dopamine across different functional circuits (MDPI, 2021; Yale University, 2024).

Other names

Nigrostriatal pathwayMesolimbic pathwayBasal ganglia dopaminergic systemDopaminergic reward system

Modulation of dopaminergic neurotransmission through receptor agonism/antagonism, reuptake inhibition, or metabolic enzyme inhibition.